Phase 3 N=42 Fish Oil Study for High Triglyceride Levels in Children
Hypertriglyceridemia
Primary: Change in Triglyceride Level — -52; -16 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=229 Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
Hypertriglyceridemia
Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -7.0; -26.6; 9.7 Percent change from baseline — p=<0.0001
N/A N=47 Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
Insulin Resistance · Hypertriglyceridemia
Primary: Pre- and Post-Intervention Triglyceride Levels — 231; 209; 201; 140 mg/dL
Phase 3 N=702 Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
Hypertriglyceridemia
Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -5.6; -17.5; 5.9 Percent change from baseline — p=<0.0001
N/A N=28 Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
Hypertriglyceridemia
Primary: Lipid Profile — 43.2; 42.7; 42.6; 130.3 mg/dL — p=0.002
Phase 4 N=48 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
HIV Infections · AIDS · Dyslipidemia
Primary: Change in Triglyceride Concentrations From Baseline in the LOVAZA Group Compared to the Placebo Group. — -34; 40 mg/dl — p=0.01
Phase 2 N=15 Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
Hypertriglyceridemia
Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid
N/A N=23 Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Difference Between Treatments in Liquid Meal Tolerance Test (LMTT) Matsuda Insulin Sensitivity Index (MISI). — 3.2; 3.3 Index value — p=0.959
Phase 2 N=114 Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
Hypertriglyceridemia · Cardiovascular Diseases
Primary: Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point — 6; -23; -56; -60 percent change — p=0.0042
Phase 3 N=551 Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
Severe Hypertriglyceridemia
Primary: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 — -56.00; -7.97 Percent of Change — p=<0.0001
Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
N/A N=130 Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.
Hypertriglyceridemia · Pediatric Obesity
Primary: Percentage Change in Serum Triglyceride Levels From Baseline to Week 12 of Study Treatment — -39.1; -14.6 Percent change (%) — p=<0.01
Phase 2 N=154 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Hypertriglyceridemia · Atherosclerotic Cardiovascular Disease · Severe Hypertriglyceridemia
Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001
Phase 2 N=177 A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
Dyslipidemia
Primary: Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -17.9; -25.0; -26.6; -2.1 Percent Change — p=<0.0001
Phase 3 N=470 Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
Severe Hypertriglyceridemia
Primary: Percent Change in Fasting TG From Baseline to Week 12 — -58.89; -22.94 Percent change — p=<0.0001
Phase 4 N=57 Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
Phase 4 N=334 Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
Hypertriglyceridemia · Hyperlipoproteinemia Type IV · Hyperlipoproteinemia Type V
Primary: Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8) — 67.95; 78.61; 22.31 mg/dL
Phase 3 N=245 Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period — -40.2; -33.7 percent change…
Phase 2 N=3 Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
Familial Chylomicronemia Syndrome · Lipoprotein Lipase Deficiency · Hyperlipoproteinemia Type 1
Primary: Absolute Change From Baseline to Month 3 in Fasting Triglycerides (TG) — -550.00 mg/dL
Phase 2 N=91 A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia · Mixed Dyslipidaemia
Primary: Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG) — -47.32; -32.95; -27.30 Percent Change — p=0.0063
Phase 4 N=65 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
High Triglycerides · Hypercholesterolemia · Schizophrenia
Primary: Change in Triglycerides From Baseline to 16 Weeks — -54.13 mg/dL
Phase 4 N=36 Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Hypertriglyceridemia · HIV Infection
Primary: Proportion of Subjects With Triglycerides <200 mg/dL — 12 participants
Phase 4 N=68 Niacin, N-3 Fatty Acids and Insulin Resistance
Metabolic Syndrome · Hypertriglyceridemia
Primary: Serum TG — 233; 157; 176; 156 mg/dl
N/A N=66 Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy
Hyperlipidemias
Primary: Triglyceride Levels — 135.5; 108.3; 152.7; 109 milligram/deciliter
Phase 3 N=113 The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — -0.9; -71.2 percent change — p=<0.0001
Phase 3 N=8,179 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Cardiovascular Diseases
Primary: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia…
Phase 3 N=503 Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 106; 110; 109 participants
Phase 4 N=41 Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
Cardiovascular Disease · HIV Infection
Primary: Change in Baseline Mean Serum Triglyceride Level at Study End — -103.0; -23.4 mg/dl
Phase 3 N=611 Efficacy of TAK-085 in Participants With Hypertriglyceridemia
Hypertriglyceridemia
Primary: Percent Change From Baseline in Triglyceride Level at the Final Visit — -10.93; -22.65; -11.30 percent change — p=0.8760
Phase 3 N=23 Fenofibrate Treatment in SCI
Spinal Cord Injury · Dyslipidemia
Primary: Triglyceride Concentration (Percent Change From Baseline) — -40; -2 percent change from baseline